cyrilzakka/clinical-trials huggingface dataset:
Wound Healing in Primary TKA

Wound complications after total knee arthroplasty (TKA) can arise from many patient-specific factors, such as vascular or immune-related medical conditions, obesity, and smoking, among others. The development of early wound complications can lead to increased length of hospital stay and more serious complications, including deep infection and major subsequent surgery. However, there are modifiable variables that could affect the risk of getting wound complications, such as the closure technique. This study aims to analyze the difference in rates of wound complications using two different closure techniques in primary TKA.


Eligibility Criteria:
Inclusion Criteria:

* Patients older than 18 years old that will undergo primary TKA with a midline approach

Exclusion Criteria:

* Previous knee arthroplasty surgeries or midline scars
* TKA secondary to oncologic or traumatic etiologies
* BMI ≥ 40
* uncontrolled diabetes (measured by a Hgb A1c above 8)
* reported allergy to skin adhesive
* immunodeficiencies
* bleeding disorders
* anticoagulation other than ASA
Dolutegravir and Clinical Outcomes Among ART-recipients in Brazil

Access to antiretroviral therapy (ART) in low-income and middle-income countries has been scaled-up effectively over recent years. Recently, the World Health Organization (WHO) guidelines changed to recommend the use of Dolutegravir (DTG) combined with two nucleoside reverse transcriptase inhibitors (NRTIs), tenofovir and lamivudine, for first-line ART; however, there is still a need for further data on the outcomes of DTG-based regimens for people with HIV-1.

This study aims to describe the outcomes of drug-naïve and experienced patients starting a dolutegravir (DTG)-based regimen in a large cohort of HIV - infected patients in Brazil and compare to outcomes obtained from a retrospective control group of subjects who initiated non-DTG-based ART.

CODE is a multicenter prospective observational study to describe and quantify the outcomes of patients starting DTG-based regimens. The investigators will follow ART-naïve patients starting DTG-based regimens (Group 1), patients on stable ART regimens switching to DTG (any reason) (Group 2), and ART-experienced patients switching to DTG-containing regimens due to virological failure (Group 3). In addition, for comparison purposes, the investigators will collect data on patients who started a non-DTG containing regimen (Group 4) in the period for 2014-2016 and did not switch to DTG-based regimens (Figure 1). Enrolled patients will be followed for 36 months.

Eligibility Criteria:
Inclusion Criteria:

* • Signed informed consent.

  * HIV infection documented by plasma HIV RNA viral load, a rapid HIV test or any licensed ELISA test; and confirmed by another test using a different method, including but not limited to a rapid HIV test, Western Blot, HIV culture, HIV antigen, or HIV pro-viral DNA at any time prior to study entry.
  * Age ≥ 15 years.
  * For women of child-bearing potential, willingness to use effective contraceptives.
  * Starting use of DTG-based regimen, or being initiated on a non-DTG based ART between 2014 - 2016.

Exclusion Criteria:

* • Any previous use of ART (drug-naïve group only).

  * Current imprisonment, or compulsory detention (involuntary incarceration). For treatment of a psychiatric or physical illness.
Left Atrial Function in Recurrent Stroke of Unknown Cause

Stroke is an important cause of disability and the third leading cause of death.

Approximately 30 to 40 % of all strokes are estimated to be cryptogenic (i.e. no cause can be found). There have been few previous studies regarding risk stratification for stroke recurrence in patients with cryptogenic stroke.

Recent studies have suggested that left atrial (LA) function is an important determinant of stroke risk. However, most studies focus on volume indices and LA dimensions, we also want to investigate other echocardiographic parameters. The aim of this study is to assess the predictive value of left atrial function for the risk of stroke recurrence and/or atrial fibrillation by transthoracic echocardiography in cryptogenic stroke patients with no proven atrial fibrillation (AF) and no indication for anticoagulants.

Study design and population The investigators used a retrospective mono-centric case-control design and analyzed all patients admitted for cerebrovascular accident (CVA) or transient ischemic attack (TIA) between 2011 and 2014. The investigators searched for patients who had a recurrent CVA/TIA and/or who were diagnosed with newly documented AF during the study duration. Clinical, demographic and laboratory parameters were assessed. Echocardiographic parameters, measured on first admission, were analyzed using EchoPAC version 112.

Statistical analysis Univariate analysis was performed for all covariates using the Cox proportional hazards model. Likelihood ratio tests were used to determine significance for all parameters.

If covariates were significant at the 25% significance level, they were used in the multivariate model.

Multivariate analysis was performed using the Cox proportional hazards model with backward elimination model selection. The Wald Chi-Square test was used to determine significance at 5% significance level. The program used for analysis is SAS version 9.4.

Eligibility Criteria:
Inclusion Criteria:

* CVA
* TIA

Exclusion Criteria:

* proven AF or atrial flutter
* prior ablation for AF
* valvular disease
* artificial heart valves
* endocarditis
* presence of an atrial septum defect or moderate to large patent foramen ovale
* LV akinesia
* moderate to severe carotid stenosis
* prior surgery for carotid artery stenosis
* total occlusion of the internal carotid artery
* carotid artery dissection
* vertebral artery dissection
* massive aortic atheromatosis
* temporal arteritis
* basilar artery aneurysm
* ascending aortic aneurysm
* subclavian steal
* prior CVA/TIA
* intracerebral hemorrhage
* lacunar infarction
* clotting disorder
* on anticoagulants
* CVA/TIA as a procedural complication
* hyperthyroidism
* patients who died in hospital after first admission for CVA/TIA
Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma

Aim of the work: Is to evaluate the prognosis of single burr hole under local anesthesia in management of CSDH according to clinical picture, risk factors, and age.

Patients and methods: We studied 67 consecutive patients with CSDH operated by single burr hole craniostomy under local anaesthesia from Mars, 2014 to February, 2015 in Zagazig University Hospitals according to the aetiology, clinical picture, risk factors, and complications.

Eligibility Criteria:
Inclusion Criteria:chronic subdural hematoma above 19 years old -

Exclusion Criteria:age below 19 years acute subduralhematoma uncoperative patients

-
Gore-BioA Fistula Plug to Treat Transsphincteric Fistulas

This is a prospective clinical study on the efficacy of Gore-BioA fistula plug in high transsphincteric fistulas. Follow-up time is six months

Inclusion criteria for the study is a patient with ultrasound or MRI proven high transsphincteric perianal fistula. Patients with Crohns disease, immunosuppressive medication, anovaginal fistula, radiation therapy or chemotherapy are excluded. A Seton is placed in the fistula track for two months before the application of the plug. Patients are followed up for six months. Symptoms of fecal incontinence before and after intervention are monitored with the Cleveland clinic incontinence score.

Eligibility Criteria:
Inclusion Criteria:

* Age 18-70 years, male or female
* High cryptoglandular perianal fistula
* Written approval for the study
* Sufficient co-operation for the study
* Localization of the fistula by ultrasound or MRI

Exclusion Criteria:

* Crohns disease
* Immunosuppressive treatment
* Anovaginal fistula
* Radiation therapy 6 months before study
* Chemotherapy 6 months before study
* Low- or intersphincteric fistula
Effect of Whey and Albumin Protein on Plasma Levels of Amino Acids

The purpose of this study will allow us to examine how quickly and to what extent plasma amino acids levels rise after ingesting a single dose of either whey or albumin protein. The investigators anticipate that the amino acids from albumin concentrate protein will rise as quickly and to the same extent as amino acids from whey protein. These findings will help us to understand the biological availability of these proteins and efficacy of the supplement so that consumers may be presented with nutritional options.


Eligibility Criteria:
Inclusion Criteria:

* normal Healthy volunteers
* free of serious illness/disease such as hypertension, kidney or liver disease

Exclusion Criteria:

* taking dietary protein or amino acid supplements
Bronchoscopy for Thoracic Trauma Patients

The study aims to evaluate the effectiveness of bronchoscopic sputum suction in patients with severe thoracic illness-induced respiratory failure. The study will compare the outcomes of patients who receive bronchoscopic sputum suction versus blind negative pressure aspiration for sputum removal. The study will measure baseline data, postoperative blood gas conditions, and clinical parameters, such as time of invasive ventilation, total time of ventilation, hospital stay, weaning success rate, reintubation rate, ventilator-associated pneumonia incidence, and fatality rate. The study aims to determine whether bronchoscopy-assisted sputum removal is superior to blind negative pressure aspiration in improving patient outcomes.

The aim of the present randomized control trial is to assess the value of bronchoscopic sputum suction in patients with severe thoracic illness-induced respiratory failure. To decrease group differences in baseline characteristics and blood gas conditions, patients will be randomly assigned to receive either bronchoscopy-assisted or negative pressure aspiration for sputum suction, while the remaining treatment course will be the same. The study will measure major clinical indicators such as time of invasive ventilation, total time of ventilation, hospital stay, weaning success rate, reintubation rate, ventilator-associated pneumonia incidence, and fatality rate to provide strong evidence for the efficacy of each suction method.

Eligibility Criteria:
Inclusion Criteria:

* Participants must be 20 years of age or older.
* Participants of all genders are eligible.
* Participants who are not in good health are not eligible.
* Participants with an Injury Severity Score greater than 9 and who have chest trauma are eligible.

Exclusion Criteria:

* Patients with traumatic brain injury.
* Patients with active pulmonary tuberculosis or other respiratory diseases with suspected contagion.
* Patients with poor blood clotting function or a tendency to bleed.
* Patients with aortic aneurysm. Patients with unstable vital signs or those who cannot maintain oxygen saturation above 90% while performing the test with Fraction of Inspired Oxygen (FiO2) greater than 80% or on 100% oxygen.
* Immunocompromised patients.
* Patients with acute massive hemoptysis.
* Patients with pre-existing neuromuscular diseases or those at high risk for arrhythmias, myocardial ischemia, or pulmonary embolism.
* Patients who are unable to clearly express their willingness to sign the informed consent form.
* Patients who have frequent intermittent sputum suction or are unable to fast for 4 hours due to their medical condition.
Effect of Electrical Muscle Stimulation in Critically Ill Patients

Electrical muscle stimulation (EMS) is the therapy used to passively activate muscles using electrodes on the surface of the skin. EMS may be helpful in preserving muscle function in people who are on bedrest due to critical illness in the intensive care unit. The purpose of this study is to determine the safety and feasibility of implementing EMS in critically ill patients who are on mechanical ventilation for greater than 7 days, and examine the effects of 4 weeks of EMS on leg muscle size, muscle strength and functional outcomes in these patients. The investigators hypothesize that EMS will be safe and feasible and that critically ill patients receiving EMS will show a smaller loss of muscle size and strength than those in the control group, who do not receive EMS.


Eligibility Criteria:
Inclusion Criteria:

* admitted to the medical-surgical ICU or cardiovascular ICU
* walking independently prior to admission
* mechanically ventilated for more than 7 days (i.e. prolonged ventilation)
* receiving enteral or parenteral nutrition.

Exclusion Criteria:

* history of neurological or psychiatric disease
* primary muscle disease (e.g. muscular dystrophy, polymyositis)
* catastrophic neurological event
* receiving palliative care
* contraindications to EMS (e.g. cardiac pacemaker/defibrillator, pregnancy, infected or cancerous lesions in proximity of electrode sites)
* inadequate access to electrode sites due to medical devices
* lower extremity edema affecting the thighs or buttocks
* BMI \> 35 kg/m2
* allergies to adhesives or latex
Knowledge and Attitude in Perioperative Erythrocyte Transfusion in Medical Personnel in Siriraj Hospital

This study is designed to explore the correlation between knowledge and attitude in perioperative erythrocyte transfusion in medical personnel.

Inappropriate erythrocyte transfusion is still have high incidence even lots of the transfusion guidelines and researches was launched. Unnecessary or delayed transfusion can cause morbidity and mortality. This study is descriptive research, questionnaire based survey conducted to explore the correlation between knowledge and attitude in perioperative erythrocyte transfusion in medical personnel in Siriraj Hospital.

Eligibility Criteria:
Inclusion Criteria:

* Post-graduated medical personnel in Siriraj Hospital

Exclusion Criteria:

* Post-graduated medical personnel in Siriraj Hospital who refuse to participate
Extracorporeal Shock Wave Therapy on Osteoblast-Like Cells In- Vitro Study

The idea of treating different deformities or diseases in the maxillofacial region with Extracorporeal Shockwave Therapy (ESWT) has recently become popular. It has been widely used in medical practice for the management of urolithiasis, cholelithiasis and in haead and neck region for sialolithiasis. The present study 'Extracorporeal Shock Wave Therapy on Osteoblast-Like Cells In-vitro study' will be done to explore and evaluate the effect of shockwaves. Further, Osteoblast-like cells will be assessed for Cell - Cell interaction and Cell Viability. It will be assessed using a scratch assay, Mtt assay and ATP analysis.

Introduction:

Extracorporeal Shockwave Therapy (ESWT) has recently become popular. Shockwave has been widely used in medical practice for the management of urolithiasis, cholelithiasis and in haead and neck region for sialolithiasis.

Aim:

This study 'Extracorporeal Shock Wave Therapy on Osteoblast-Like Cells In-vitro study' will be done to explore and evaluate the effect of shockwaves. Further, Osteoblast-like cells will be assessed for Cell - Cell interaction and Cell Viability.

Methodology:

In this in-vitro study, 20 Osteoblast - like cells will be included. 10 samples to be considered for Control group and the remaining 10 samples considered as Test group. Extracorporeal shockwave will be applied to the Test samples. They will be further analysed using wound scratch assay which is used to assess Cell proliferative rate and scratch closure through live imaging. MTT assay and ATP assay used to determine Cell viability after exposure to shockwaves. The cell migration and cell viability after exposure to shockwaves will determine its effects on osteoblast-like cells.

Eligibility Criteria:
Inclusion Criteria:

* Cell cultures with a confluency of 70%-80%

Exclusion Criteria:

* Contaminated cell cultures
Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors

Pancreatic radiofrequency ablation (RFA) could therefore be an alternative to the monitoring of pancreatic neuroendocrine tumors (PNETs) and more particularly nonfunctioning PNETs (NF-PNETs), which is costly and anxiety-inducing for patients. To date, only a few small studies have evaluated this treatment and the results are encouraging. It appears necessary to consider a large-scale study to ensure the efficacy and low morbidity of pancreatic RFA applied to PNETs.

The primary objective of the study is to evaluate the efficacy of radiofrequency treatment of grade 1 NF-PNETS with a size less than or equal to 2cm.

Patients meeting the selection criteria will be included in the study after signing the consent. They will benefit from a RFA treatment consisting of 1 to 3 sessions depending on their response to the treatment. Patients will then be followed for 5 years in order to evaluate their response to treatment, their clinical evolution, their quality of life and any complications.

Eligibility Criteria:
Inclusion Criteria:

* Pancreatic mass of less than 2cm on MRI, or CT scan if contraindicated by MRI;
* Diagnosis of neuroendocrine tumor on biopsy under high echo-endoscopy (HEE) with Ki67\<3%,
* Non-secretory lesion.
* Homogeneous HEE contrast taking;
* No positron emission tomography (PET) FDG binding to the pancreatic mass;
* Lesion \<20mm on conventional imaging at 6 months monitoring;
* Age 18 to 80 years inclusive;
* Patient in good general condition, World Health Organization \[0-1\];
* Signed consent to participate;
* Affiliation to healthcare insurance system or beneficiary of this regimen.

Exclusion Criteria:

* Pregnant or likely to become pregnant (without effective contraception) or breastfeeding ;
* A person in an emergency situation or deprived of liberty or placed under the authority of a tutor.
* Life expectancy \< 1 year;
* Severe hemostasis disorders;
* Pancreatic and/or biliary ductal dilation;
* Lesion considered to be adjacent to the pancreatic duct and/or bile duct;
* Node extension and/or metastatic disease;
* Patient being managed for another malignant lesion which is progressive or under treatment.
Incidence of MRI Sacro-Iliac (SI) Joint Anomalies in Women With Spondyloarthritis (SpA)

Retrospective study comparing the incidence of inflammatory and structural lesions seen on MRI of the sacro-iliac (SI) joints in a population of women affected by spondyloarthritis (SpA) and control women population (MISIA study NCT02956824).

A previous study (MISIA) demonstrate SpA may be misdiagnosed on MRI in postpartum women due to increased stress on the joint following pregnancy and childbirth, as MRI of the SI joints may show lesions that could mimics SpA.

The primary objective of this study is to compare the incidence and pattern of MRI inflammatory and structural lesions of the SI joints between SpA and control women, and determine differentiation criteria in SpA women.


Eligibility Criteria:
Inclusion criteria:

* Women aged 18 to 50 years old
* SpA diagnosed
* Pelvis MRI performed

Exclusion criteria:

- Pelvis MRI unavailable
Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis

Exploratory, multi-centric, randomized, vehicle-controlled, investigator-blind, parallel group study, involved participants with chronic lesions of Atopic Dermatitis (AD) to evaluate the local and systemic safety of CD5024 0.3% cream over a 6-week treatment period compared to its vehicle.

Study application was performed once daily, 7 days a week for 6 weeks.

Eligibility Criteria:
Inclusion Criteria:

1. The participant was a male or female aged 18 to 60 years old inclusive at Screening.
2. The participant presented with a total body surface area (tBSA) less than or equal to (\>=) 2 square meter (m\^2) at Screening.
3. The participant had atopic dermatitis for at least 6 months prior to Day 1. The clinical diagnosis of atopic dermatitis must be confirmed with the criteria of Hanifin and Rajka at the screening visit.
4. Atopic dermatitis must be stable for at least one month before the screening visit (according to participant).
5. The participant had a Body Surface Area (BSA) affected by AD ranging from 1% inclusive to 10% inclusive at Day 1, excluding scalp and genitals.
6. The participant had an overall Investigator's Global Assessment (IGA) score of 3 (moderate) at Day 1;

Exclusion Criteria:

1. The participant was a pregnant female, is breastfeeding or intends to conceive a child during the study,
2. The participant had any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with the interpretation of the clinical trial results (e.g. extensive scaring or pigmented lesion in a treated area), and/or put the participant at significant risk according to Investigator's judgment if he/she participates in the clinical trial (e.g. active cancer, AIDS, insulin-dependent diabetes...) at Screening or Day 1.
3. The participant presented with an acute flare of AD at Day 1.
4. The participant had active cutaneous bacterial or viral infection in any treated area at baseline (e.g. clinically infected AD) at Screening or Day 1.
5. The participant had a history of confounding skin condition (e.g. psoriasis, erythroderma) or a history of Netherton syndrome at Screening.
6. The participant had a past history of serious persistent neurological disorders such as seizures, multiple sclerosis, or neurological signs or symptoms at Screening.
Nexium Capsules RE Maintenance Specific Clinical Experience Investigation

The purpose of this study is to collect following data in patients given Nexium capsule (Nexium) in usual post-marketing use as the maintenance therapy for repeatedly recurring/relapsing reflux oesophagitis.

Nexium capsules Specific Clinical Experience Investigation for Maintenance Therapy for Repeatedly Recurring/Relapsing Reflux Oesophagitis

Eligibility Criteria:
Inclusion Criteria:

* Patients with repeatedly recurring/relapsing reflux oesophagitis who will be given Nexium for the first time as a maintenance therapy.

Exclusion Criteria:

* Patients having reflux oesophagitis when Nexium is started (Grade A, Grade B, Grade C or Grade D of Los Angeles Classification (Hoshihara's modification) on endoscopy)
* Patients having previous history of maintenance therapy for repeatedly recurring/ relapsing reflux oesophagitis